Neuphoria Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Neuphoria Therapeutics Inc. (NEUP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 51.84 thousand shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-09-18
- Neuphoria Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- Neuphoria Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 51.84K shares.
- Neuphoria Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 40.50K shares.
- Neuphoria Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2026 was 51.84K shares, a 28.00% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 40.50K shares.
- Neuphoria Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 43.10M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 51.84K shares 10-K · filed 2026-09-18 | |||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | |||
| 2025-09-30 | 51.84K shares 10-Q · filed 2026-05-15 | 92.34K shares derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2025-06-30 | 40.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | 40.50K shares 10-K · filed 2025-09-29 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | |||
| 2023-06-30 | 43.10M shares 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |